CD20 is a B-cell-specific marker that has been used extensively as a target for antibody (Ab) therapy in patients with B-cell lymphoma. Unconjugated Abs have become established as standard therapy ...
HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase 1 and PK study Ca++ mobilization leading to ...
Clinical and dynamic imaging results of the first phase I study of AG–013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors No significant financial relationships to ...
Preclinical study of 212 Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma SDS polyacrylamide gel electrophoresis and western blot analysis of the fusion protein The fusion protein ...
CD20 expression levels correlate with outcomes in B-cell lymphoma patients treated with CD20xCD3 bispecific antibodies. Patients with reduced CD20 expression had significantly lower PFS and OS rates ...
NK cell-related immunotherapeutics, such as tumor-specific monoclonal antibodies (mAbs) to elicit NK cell-mediated ADCC against tumor cells, are being developed for the treatment of cancers. As an ...
The review concludes that CD20-targeted chimeric antigen receptor (CAR) T-cell therapy is an option worth exploring, despite potential safety concerns that warrant more extensive research. CAR T-cell ...
CAR-T Target Luciferase Reporter Cells can be used as a target cancer cell for in vitro killing assay by CD19, CD20, or HER2 CAR-T cells. These luciferase expressing cell lines were derived from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results